Oncology Stocks: 8 Biggest NASDAQ Companies in 2026
The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.
Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.
The space is seeing significant advancements with innovative new therapies. As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on cancer drugs, vaccines and therapies.
This list of the biggest oncology stocks on the NASDAQ was generated using TradingView’s stock screener. The companies are listed in order of market cap, and all figures below were current as of August 19, 2026.
1. Amgen (NASDAQ:AMGN)
Market cap: US$239.15 billion
Share price: US$442.36
One of the world’s leading independent biotechnology companies, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting oncological diseases, including a range of solid tumors and hematologic malignancies.
Amgen’s lung cancer therapy Imdelltra posted 115 percent year-over-year sales growth in the second quarter, and several of its other cancer treatments including blood cancer drug Blincyto posted double digit growth, which the company attributed to increases in volume.
During the quarter, Imdelltra also gained EU approval for extensive-stage small cell lung cancer and full approval in China.
However, two studies testing a subcutaneous version of Blincyto paused enrollment after the US Food and Drug Administration (FDA) placed a partial clinical hold. Amgen says it’s discussing next steps with the agency.
The company’s prostate cancer candidate, xaluritamig, completed enrollment in its XALute Phase 3 trial during Q2, while Amgen’s KRAS inhibitor Lumakras remains in two ongoing Phase 3 studies for colorectal and lung cancer.
2. Gilead Sciences (NASDAQ:GILD)
Market cap: US$183.02 billion
Share price: US$147.60
Global biopharmaceutical company Gilead Sciences is in the business of developing breakthrough medicines to prevent and treat serious conditions such as HIV, viral hepatitis and cancer. The company has built up its early oncology pipeline with the acquisition of biotech firm XinThera and its portfolio of small molecule inhibitors targeting PARP1.
One of Gilead’s biggest successes is Yescarta, a CAR-T cell therapy for blood cancer and the first such therapy for certain types of non-Hodgkin’s lymphoma.
The company also has its breast cancer treatment Trodelvy, which the FDA approved for metastatic triple-negative breast cancer in 2020. Sales of Trodelvy grew sales 26 percent year-over-year in the second quarter of 2026, helped…
